GFE and LVL Technologies strengthen supply of COVID-19 antigen tests

Frankfurt am Main; Crailsheim, March  12, 2021. – GFE and LVL Technologies today announced to strengthening their long cooperation for the current sales and support of PCL’s COVID-19 antigen rapid test, whereas both companies combine their specific core competences to strengthen the market position.

“This cooperation is a major milestone to address the increasing demands of the highly volatile COVID-19 market for continuous supply and very fast delivery processes” said Dr. Reiner Babiel, CEO at GFE.

“With our well established international logistic and supply chain we are well positioned to satisfy high logistical challenges in the current Corona pandemic.” comments Martin von Lueder, CEO at LVL.

GFE’s experiences in IVD products and regulations provides the solid basis for the regulatory compliance and a professional support of customers.

LVL’s strength in international logistics guarantees a well-established  supply chain for the increasing demands of the  antigen test market during the Corona pandemic.

Jointly the two companies want to provide superior customer experience and product availability to help successfully fighting the Corona crisis.

LVL is a privately owned company for laboratory supplies with a long history in MedTech and Pharma industries.

GFE is a wholly owned subsidiary of the three German Red Cross organisations DRK Blutspendedienst West, DRK Blutspendedienst NSTOB, and Blutspendedienst des Bayerischen Roten Kreuzes.

 

Contact:

LVL technologies GmbH & Co. KG
Theodor-Storm-Straße 17
74564 Crailsheim
T +49 7951 95613-20
www.lvl-technologies.com

GFE
Altenhöferallee 3
60438 Frankfurt am Main
T +49 69 400 5513-0
www.gfeblut.de

PoET HIV CE-IVD marked

Frankfurt am Main, March 12, 2021. – GFE announced the CE-IVD approval of its PoET HIV blood screening NAT test. The PCR kit is used on GFE’s new, fully integrated NAT testing solution, the PoET System. With this NAT test GFE continues its tradition as a leading provider of high-quality blood screening solutions.

“Despite a variety of powerful therapies, there is still no cure for or vaccination to prevent HIV infections. Therefore, transmission risk reduction particularly regarding transfused blood or blood components remains a key priority.” said Dr. Reiner Babiel, CEO at GFE. “Our Assay Development has redesigned the HIV assay, now allowing to detect all HIV clades including HIV-2 in one assay, either in screening or confirmatory format. In total five amplicons seamlessly work together to achieve superior performance and safety.”

The CE approval marks a major milestone in the launch process for the PoET product line. The PoET system features a fully automated instrument and on top of HCV, HBV and HIV an extensive menu for blood screening tests, including HAV, B19V, HEV and WNV. The market introduction of the PoET product line is scheduled for spring 2021.

The PoET HIV test features excellent sensitivity and a broad subtype coverage to effectively address the serology window period. The test is designed for mini pool testing as well as confirmatory testing of individual donations. Effective mini pool testing enables laboratories to increase sample throughput at lower costs per sample while maintaining very high blood safety standards.

GFE is a wholly owned subsidiary of the three German Red Cross organizations DRK Blutspendedienst West, DRK Blutspendedienst NSTOB, and Blutspendedienst des Bayerischen Roten Kreuzes.

GFE’s PoET HCV receives CE-IVD mark

Frankfurt am Main, January 22, 2021. – GFE today announced the CE-IVD approval of its PoET HCV blood screening NAT test. The PCR kit is used on GFE’s new, fully integrated NAT testing solution, the PoET System. With this NAT test GFE continues its tradition as a leading provider of high-quality blood screening solutions.

“Hepatitis C played a key role in establishing nucleic-acid based screening of donor blood in the late 1990ies. Since there is still no vaccination against HCV, sensitive screening remains an effective tool to control the spread of this virus.” said Dr. Reiner Babiel, CEO at GFE.

The CE approval marks another major milestone in the launch process for the entire PoET product line. The PoET system features a fully automated instrument and a series of blood screening tests. The market introduction of the PoET product line is scheduled for spring 2021.

The PoET HCV test features excellent sensitivity and a broad genotype coverage to effectively address the serology window period. The test is well suited for mini pool testing as well as confirmatory testing of individual donations. Effective mini pool testing enables laboratories to increase sample throughput at lower costs per sample while maintaining very high blood safety standards.

GFE is a wholly owned subsidiary of the three German Red Cross organisations DRK Blutspendedienst West, DRK Blutspendedienst NSTOB, and Blutspendedienst des Bayerischen Roten Kreuzes.